Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bayer
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients who have completed 16 weeks of treatment in the double blind trial CHEST 1
You may not be if
Patients who have an ongoing serious adverse event from CHEST 1 that is assessed as related to BAY63-2521 are not allowed to participate in the extension trial
Clareo Health | BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension
